#USA #Viralgen #CDKL5 Deficiency #Elaaj Bio #San Sebastián, Spain

Viralgen and Elaaj Bio: A Transformative Collaboration

Viralgen, a prominent contract development and manufacturing organization (CDMO), has announced a strategic partnership with Elaaj Bio, a biopharmaceutical company focused on groundbreaking therapies for CDKL5 deficiency disorder (CDD). This collaboration aims to advance a preclinical gene therapy program targeting a rare neurological condition that significantly impacts children.

Understanding CDKL5 Deficiency Disorder

CDKL5 deficiency disorder is a severe developmental and epileptic encephalopathy caused by mutations in the CDKL5 gene. This disorder is often characterized by early-onset seizures and profound neurological developmental delays, greatly affecting not only patients but also their families. Current research and therapy aimed at addressing this condition are limited, which highlights the critical need for innovative treatments.

The Collaboration Details

Under this partnership, Viralgen will leverage its expertise in producing adeno-associated viral vectors (AAV) to support key developmental activities in the project. This includes optimizing production processes and ensuring quality control throughout the manufacturing stages. Initial developmental work has already shown the technical feasibility of the production approach, and current efforts are focused on scaling up the process for larger batch production.

Jimmy Vanhove, CEO of Viralgen, emphasized the importance of collaborations like this one, stating, "Such partnerships are essential for advancing complex gene therapy programs, particularly in rare pediatric diseases where the demand for new therapies and innovations remains high." Vanhove noted that by combining strengths from both Viralgen and Elaaj Bio, they are accelerating the clinical development of ELJ-101, the proposed gene therapy for CDD.

The Next Steps

The teams involved anticipate launching the first clinical study for this innovative therapy, ELJ-101, by early 2027. To further bolster clinical development, efforts are concentrating on refining and scaling manufacturing processes.

Commitment to Finding Solutions

Russ Addis, Head of Pipeline Strategy and Genetic Medicine at the Loulou Foundation, which owns Elaaj Bio, remarked, "Everything we do is mission-driven, focusing on developing treatment options for CDD." Addis expressed hope that the collaboration with Viralgen would lead to an effective gene therapy addressing the underlying cause of CDKL5 deficiency.

About Viralgen

Founded in 2017 as a subsidiary of AskBio, Inc. within the Bayer AG group, Viralgen specializes exclusively in gene therapies based on AAV. The company offers end-to-end support from early development to large-scale manufacturing. Utilizing proprietary technologies, such as the Pro10™ suspension cell line and Aava™ manufacturing platform, Viralgen achieves high productivity and scalability in AAV production. Their state-of-the-art facility in San Sebastián, Spain, includes three certified cGMP facilities, demonstrating their commitment to quality and efficiency.

About Elaaj Bio and the Loulou Foundation

Elaaj Bio operates as a wholly-owned subsidiary of the Loulou Foundation, a UK-based private non-profit dedicated to advancing research into CDD. The foundation funds studies in leading universities across the U.S. and Europe, enabling focused research efforts that contribute significantly to understanding and treating CDKL5-related disorders. The Loulou Foundation also hosts the CDKL5 Forum, an annual conference that has become a vital platform for discussing fundamental and clinical research on CDD.

Conclusion

The partnership between Viralgen and Elaaj Bio marks a significant step in the pursuit of innovative therapies for CDKL5 deficiency disorder. By combining their expertise and resources, both organizations are well-positioned to make a meaningful impact in the lives of children affected by this serious condition and to advance the state of gene therapy research.